Bone Biologics (NASDAQ:BBLG) Issues Quarterly Earnings Results

Bone Biologics (NASDAQ:BBLG) released its quarterly earnings results on Thursday. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11, FiscalAI reports.

Bone Biologics Trading Up 1.2%

Shares of NASDAQ:BBLG opened at $1.29 on Friday. Bone Biologics has a twelve month low of $1.05 and a twelve month high of $6.75. The company’s 50 day moving average is $1.26 and its 200 day moving average is $1.50. The company has a market cap of $2.31 million, a PE ratio of -0.57 and a beta of 0.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC lifted its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Institutional investors and hedge funds own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.